



Trial Information Summary

ALLG Trial Number:	AML17
Trial Name:	A Strategy of High-Dose Lenalidomide in Combination with Epigenetic Therapies for Relapsed or Refractory Acute Myeloid Leukaemia
Lay Summary:	<p>Acute Myeloid Leukaemia (AML) is diagnosed in over 800 Australians each year. Half of these patients are under the age of 60 and many will relapse, despite being in remission after treatment with chemotherapy.</p> <p>Treatment options for these patients with relapsed AML are limited and difficult.</p> <p>This study will look at using high dose lenalidomide with one of two other therapies in patients with relapsed AML.</p>
Participating Hospitals:	1. Alfred / 2. Gosford / 3. Queen Elizabeth
Target Accrual (International):	N/A
Target Accrual (ALLG):	Phase I study – up to 18 participants. Phase II study – 120 patients.
Expected Final Accrual Date:	March 2018